🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsOral GLP-1 AgonistsRybelsus real-world vs clinical trial efficacy — the gap explained Page 2

Rybelsus real-world vs clinical trial efficacy — the gap explained

BiostatsBrad Thu, May 21, 2026 at 5:35 AM 23 replies 904 viewsPage 2 of 5
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
May 21, 2026 at 7:45 AM#6

The figures, for anyone assembling their own picture. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.

Worth separating that from the trial evidence, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Last edited: May 21, 2026 at 8:45 AM
28 23rachel_ABQ, traveltech_sara, AttorneyGrant and 25 others
Reply Quote Save Share Report
pam_stl
Member
267
1,123
Oct 2024
St. Louis, MO
May 21, 2026 at 8:35 AM#7

Following on from pat_auckland — and this may be the naive question:

Whether the fasting requirement is as strict in practice as the label implies, and what people actually see when they get it wrong?

27 22HealthEcon_DC, PedsEndoPhilly, SleepDoc_PDX and 24 others
Reply Quote Save Share Report
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
May 21, 2026 at 9:25 AM#8
Dr.PulmRoch said:
A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator.

There is a second half to this that has not been said yet. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

26 21ingrid_STO, pete_nash, hank_denver and 23 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
BiostatsBrad
Member
456
2,345
Jul 2024
Durham, NC
May 21, 2026 at 10:15 AM#9

Reporting back.

I moved the tablet to the moment I wake up rather than trying to fit it around breakfast, and the difference in the following weeks was obvious. It was a timing problem, not a dose problem.

25 20james_edin, FranDenver, Dr.BariatricHTX and 22 others
Reply Quote Save Share Report
pete_nash
Member
312
1,345
Aug 2024
Nashville, TN
May 21, 2026 at 2:14 PM#10
NurseKim_ATL said:
The gap between trial results and real-world results is consistent and it is not fraud.

NurseKim_ATL has the substance of this right. The condition it depends on is worth stating. Worth adding that the tablet is taken daily, so a missed dose costs far less than a missed weekly injection. That is a genuine advantage nobody lists.

49 22sarah.morrison, NeuroNate, JessicaH_TX and 46 others
Reply Quote Save Share Report

Similar Threads

Orforglipron Phase 3 ATTAIN-1 topline — oral non-peptide GLP-116 replies
Oral semaglutide 50mg (Rybelsus HD) — OASIS program results12 replies
Danuglipron BID dosing — Pfizer oral GLP-1 update7 replies
Oral vs injectable GLP-1: bioavailability and efficacy comparison5 replies
Orforglipron food interaction profile — no fasting requirement15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register